[1] |
Jadvar H. Molecular imaging of prostate cancer: a concise synopsis. Mol Imaging, 2009, 8(2): 56-64.
|
[2] |
中华医学会泌尿外科分会. 前列腺癌诊断治疗指南. 中华现代外科学杂志, 2006, 3(22): 1839-1856.
|
[3] |
Anastasi A, Erspamer V, Bucci M. Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes. Experientia, 1971, 27(2): 166-167. doi: 10.1007/BF02145873
|
[4] |
Cornelio DB, Roesler R, Schwartsmann G. Gastrin-releasing pep-tide receptor as a molecular target in experimental anticancer therapy. Ann Oncol, 2007, 18(9): 1457-1466. doi: 10.1093/annonc/mdm058
|
[5] |
Markwalder R, Reubi JC. Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res, 1999, 59(5): 1152-1159.
|
[6] |
Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol, 2008, 53(5): 890-900. doi: 10.1016/j.eururo.2007.12.021
|
[7] |
Schroeder RP, van Weerden WM, Bangma C, et al. Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods, 2009, 48(2): 200-204. doi: 10.1016/j.ymeth.2009.04.002
|
[8] |
Yang YS, Zhang X, Xiong Z, et al. Comparative in vitro and in vivo evaluation of two 64Cu-labeled bombesin analogs in a mouse model of human prostate adenocarcinoma. Nucl Med Biol, 2006, 33(3): 371-380. doi: 10.1016/j.nucmedbio.2005.12.011
|
[9] |
Duncan JR, Stephenson MT, Wu HP, et al. Indium-111-diethylene-triaminepentaacetic acid-octreotide is delivered in vivo to pancre-atic, tumor cell, renal, and hepatocyte lysosomes. Cancer Res, 1997, 57(4): 659-671.
|
[10] |
Maecke HR, Hofmann M, Haberkorn U. (68)Ga-labeled peptides in tumor imaging. J Nucl Med, 2005, 46 (Suppl 1): 172S-178S.
|
[11] |
Maina T, Nock B, Mather S. Targeting prostate cancer with radiola-belled bombesins. Cancer Imaging, 2006, 6: 153-157. doi: 10.1102/1470-7330.2006.0025
|
[12] |
Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med, 2006, 47(3): 492-501.
|
[13] |
Chen X, Park R, Hou Y, et al. Micro PET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med, 2004, 45(8): 1390-1397.
|
[14] |
Lantry LE, Cappelletti E, Maddalena ME, et al. 177Lu-AMBA: syn-thesis and characterization of a selective 177Lu-labeled GRP-R ago-nist for systemic radiotherapy of prostate cancer. J Nucl Med, 2006, 47(7): 1144-1152.
|
[15] |
Johnson CV, Shelton T, Smith CJ, et al. Evaluation of combined (177)Lu-DOTA-8-AOC-BBN(7-14)NH(2) GRP receptor-targeted radiotherapy and chemotherapy in PC-3 human prostate tumor cell xenografted SCID mice. Cancer Biother Radiopharm, 2006, 21(2): 155-166. doi: 10.1089/cbr.2006.21.155
|